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Disease progression in amyotrophic lateral sclerosis (ALS) is characterized by degeneration
of motoneurons and their axons which results in a progressive muscle weakness and
ultimately death from respiratory failure. The only approved drug, riluzole, lacks clinical
efficacy so that more potent treatment options are needed. We have identified rho kinase
(ROCK) as a target, which can be manipulated to beneficially influence disease progression
in models of ALS. Here, we examined the therapeutic potential of the ROCK inhibitor
Y-27632 in both an in vitro and in an in vivo paradigm of motoneuron disease. Application
of Y-27632 to primary motoneurons in vitro increased survival and promoted neurite
outgrowth. In vivo, SOD1G93A mice were orally treated with 2 or 30mg/kg body weight of
Y-27632. The 2mg/kg group did not benefit from Y-27632 treatment, whereas treatment
with 30mg/kg resulted in improved motor function in male mice. Female mice showed
only limited improvement and overall survival was not modified in both 2 and 30mg/kg
Y-27632 groups. In conclusion, we provide evidence that inhibition of ROCK by Y-27632 is
neuroprotective in vitro but has limited beneficial effects in vivo being restricted to male
mice. Therefore, the evaluation of ROCK inhibitors in preclinical models of ALS should
always take gender differences into account.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease
which is characterized by degeneration of the first and sec-
ond motoneuron resulting in severe progressive muscle weak-
ness and most often death from respiratory insufficiency within
only a few years after initial diagnosis. It is known to be a
neurodegenerative process that comprises the loss of motoneu-
ronal cells, of their axons and neuromuscular junctions but also
non-neuronal cell populations contribute to the progression of
disease. Because first pathological signs of motoneuron degen-
eration are observed at the distal end of its axonal projections
some authors consider ALS to be a distal axonopathy (Fischer and
Glass, 2007). The molecular and pathophysiological mechanisms
of the disorder are multifactorial and include protein aggregation,
oxidative stress, excitotoxicity, mitochondrial dysfunction, and
impaired axonal transport (Ferraiuolo et al., 2011). Moreover,
there is a strong involvement of glial cells such as astrocytes,
microglia and oligodendrocytes, which may determine the onset
and the dynamics of disease progression (Philips and Robberecht,
2011).
Abbreviations: ANOVA, analysis of variance; MAPKAP-K1b, MAPK-activated
protein kinase-1b; MN, motoneuron; MSK1, mitogen- and stress-activated pro-
tein kinase 1; PKA, cAMP-dependent protein kinase; ROCK, rho kinase; S6K1, p70
ribosomal protein S6 kinase; SMA, spinal muscular atrophy; SOD1G93A, superox-
ide dismutase 1 G93A transgenic; Veh, vehicle; Y2, Y-27632 2mg/kg body weight;
Y30, Y-27632 30mg/kg body weight.
Apart from the majority of sporadic forms, there exist at least
10% of familial forms of ALS (fALS). Among these, genetic muta-
tions in the super oxide dismutase gene 1 (SOD1) were identified
first and today represent about 20% of all familial forms (Rosen
et al., 1993). Recently, many other familial cases have been iden-
tified which exhibit mutations e.g., in Fused in sarcoma (FUS),
TAR DNA-binding protein 43 (TDP-43) or exhibit an intronic
hexanucleotide repeat in the gene C9orf72. The C9orf72 repeat
expansion is considered to be the most frequent genetic alteration
in fALS patients but has also been identified inmany patients with
sporadic ALS (sALS). Therefore, longstanding concepts of the
cause and molecular pathology in ALS are currently re-evaluated
(Turner et al., 2013).
The fALS gene mutations have permitted the generation of
transgenic mouse models of ALS. Because it closely recapitu-
lates human disease progression the SOD1G93A mouse model
has evolved as a standard model for the evaluation of thera-
peutic effects in preclinical studies (Turner and Talbot, 2008). A
variety of neuroprotective agents have been examined to both
delay the onset of clinical disease and to prolong the disease
course ultimately extending life span in animal models, but only
the glutamate antagonist riluzole has reached clinical use so far
(Benatar, 2007). However, this agent has very limited benefits in
ALS patients (Stewart et al., 2001).
Rho kinases (ROCK) are serine/threonine kinases that regulate
cytoskeleton structure through phosphorylation of LIM kinases,
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myosin light chain or the ezrin/radixin/moesin protein com-
plex (Tonges et al., 2011). Our group and others have shown
that inhibition of ROCK with pharmacological small molecule
inhibitors is not only able to improve the regenerative response
in the lesioned CNS (Lingor et al., 2008; Planchamp et al., 2008;
Bermel et al., 2009), but also exerts neuroprotection via activa-
tion of intracellular cell survival signaling such as the Akt pathway
(Tonges et al., 2012; Takata et al., 2013). In addition, we have
recently demonstrated that the use of fasudil, a small-molecule
ROCK inhibitor of the isoquinoline series, strongly modulates
microglial function in SOD1G93A female mice which may be a
major component of the therapeutic effect (Tonges et al., 2014).
Based on these results, we have designed both an in vitro
and an in vivo study to evaluate the neuroprotective potential
of ROCK inhibition with a more specific ROCK inhibitor, the
4-aminopyridine derivative Y-27632.
MATERIALS AND METHODS
MOTONEURON PREPARATION
Lumbar spinal cord mouse motoneurons (MN) of E11.5–E13.5
embryos of wild type (WT) mice (B6/SJL background) were
generated applying a preparation technique adapted from Wiese
et al. (2010). In the case of later immunoblot and cell
toxicity analysis the panning step was omitted in order to
obtain a higher cell yield. In all cases, cells were collected
and seeded on poly-L-ornithine/laminin coated cover slips in
MN complete medium containing Neurobasal medium with-
out (2)L-Glutamine (Invitrogen, Darmstadt, Germany), supple-
mented with 2% horse serum (Linaris, Wertheim, Germany),
B27-supplement (Invitrogen, Darmstadt, Germany), BDNF (final
concentration 10 ng/mL; Tebu Bio, Offenbach, Germany), and
CNTF (final concentration 10 ng/mL; Tebu Bio, Offenbach,
Germany) at a density of 25,000 cells/cm2.
MOTONEURON CULTURE, QUANTIFICATION OF CELLULAR SURVIVAL,
CYTOTOXICITY AND NEURITE LENGTH
MN were cultured in MN complete medium and supplemented
with Y-27632 (final concentration 10µM; Sigma-Aldrich, St.
Louis, Mo) or the respective amount of vehicle every sec-
ond day. Additionally, BDNF and CNTF (final concentration
10 ng/mL, both Tebu Bio) were supplemented every second
day. Motoneuron survival was assessed by counting ChAT-
immunopositive cells after fixation and immunocytochemistry
on DIV4.
Cytotoxicity assays were also done on DIV4. Here, a
bioluminescence-based assay for the release of adenylate kinase
(AK) from lesioned cells was applied according to the man-
ufacturer’s instructions (ToxiLight®, Lonza, Wakersville, USA).
Briefly, the amount of adenylate kinase (AK) was determined
in the culture medium by measuring the AK-dependent conver-
sion of ADP to ATP and subsequent light emission by luciferase
with a luminometer (Wallac 1450MicroBeta Trilux, PerkinElmer,
Shelton, USA).
The length of all neurites of ChAT-immunopositive cells was
evaluated semi-automatically using the axon tracing module of
“Image J” (Free Java software provided by the National Institutes
of Health, Bethesda, Maryland, USA) and was divided by the
numbers of ChAT-immunopositive cells in order to obtain neu-
rite length/cell. Results were expressed in relation to vehicle
treated cells. The immunofluorescence-based quantification of
intracellular ROCK2 protein was done by measuring mean flu-
orescence intensity values in MN perikarya with “ImageJ.” For
MN survival at least three and for neurite outgrowth at least
two independent experiments were evaluated. The quantification
of perikaryal ROCK2 was done in at least 6 MN per treatment
condition.
IMMUNOCYTOCHEMISTRY
ForMN immunolabeling, cells were fixed in PFA 4% for 10min at
room temperature (RT, 22◦C), permeabilized with 100% ice-cold
acetone (AppliChem, Darmstadt, Germany) 10min at −20◦C,
washed twice with PBS and blocked with 10% normalized
goat serum 10min at RT. Probes were incubated with the pri-
mary antibodies (rabbit anti ChAT 1:50, Millipore, Schwalbach,
Germany; goat anti-ROCK2 1:50, Santa Cruz Biotechnology Inc.,
Heidelberg, Germany) for 1 h at 37◦C or were fixed in PFA 4%
for 10min at room temperature (RT, 22◦C), washed twice with
PBS, incubated 30min in 25mM Glycine in PBS (Applichem,
Darmstadt, Germany), permeabilized and blocked with 10%
horse serum, 5% BSA, 0,3% Triton, 25mM Glycine in PBS at
RT for 1 h and then incubated with primary antibodies (rabbit
anti ChAT 1:50, Millipore, Schwalbach, Germany; mouse anti-
MAP2 1:500 Chemicon/Millipore, Schwalbach, Germany) over
night at 4◦C.
Following three PBS washes, Cy3- or Cy2-labeled secondary
antibodies (1:250, Dianova, Hamburg, Germany) were applied
for 1 h at room temperature. After another three PBS washes, cells
were then nuclear counter-stained with DAPI (4,6-diamidino-2-
phenylindole) (Sigma, Taufkirchen, Germany), optionally incu-
bated with additional Rhodamine-Phalloidin 1:500 in PBS
(Invitrogen, Eugene, Oregon, USA) and mounted in Mowiol
(Hoechst, Frankfurt, Germany). Immunolabeled fluorescent cells
were imaged on a Zeiss Axioplan 2 fluorescence microscope
equipped with a CCD camera and AxioVision software (Zeiss,
Göttingen, Germany). For evaluation of survival and neurite out-
growth of ChAT-immunopositive cells, micrographs were taken
with a 10× objective of at least four random visual fields per
culture well and of at least two wells per condition.
MOTONEURON CELL CULTURE LYSIS AND IMMUNOBLOTTING
Motoneuron cultures were plated at a density of 25,000 cells/cm2,
cultured in MN complete medium and supplemented with Y-
27632 (final concentration 10µM; Sigma-Aldrich, St. Louis, Mo)
or the respective amount of vehicle every second day. After 5
days cells were lysed with a cell lysis buffer (Thermo Scientific™
Pierce™ RIPA Buffer, Thermo Fisher Scientific Inc., Waltham,
MA USA) plus protease inhibitors (“Complete tablets,” Roche,
Basel, Switzerland) and phosphatase inhibitor (“PhosSTOP,”
Roche, Basel, Switzerland). The protein content of all cell sam-
ples was determined using Bradford (Biorad, Munich, Germany)
and equal amounts of protein (20µg) were separated on a sodium
dodecyl sulfate–polyacrylamide gel electrophoresis.
Proteins were then electrotransferred onto a PVDF membrane
(Applichem, Darmstadt, Germany) and blocked with 5% milk in
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Tris-buffered saline/Tween-20 (TBS-T) for 1 h. Membranes were
then incubated with the primary antibodies goat anti-ROCK2
1:50 (Santa Cruz Biotechnology Inc., Heidelberg, Germany) and
mouse anti-GAPDH 1:1000 (HyTest Ltd, Turku, Finland) in
5% milk TBS-T or 5% BSA TBS-T over night at 4◦C. This
was followed by incubation with corresponding horseradish
peroxidase-coupled secondary antibodies (1:1000 for 1 h at
room temperature; Dianova, Hamburg, Germany). ECL-Plus
reagent (Amersham, Arlington Heights, IL, USA) was applied
on the membrane and the chemiluminescence was visualized
on an Amersham Hyperfilm ECL (GE Healthcare, Chalfont St
Giles, GB).
ANIMAL HOUSING, BREEDING, GENOTYPING AND APPLICATION OF
Y-27632
All animal experiments were carried out according to the reg-
ulations of the local animal research council and legislation
of the State of Lower Saxony. High-copy number B6/SJL-
Tg(SOD1∗G93A)1Gur/J (labeled as SOD1G93A in the following
text) (Gurney et al., 1994) were obtained from Jackson Labs
(Stock Number 002726; Bar Harbor, USA). The colony was main-
tained by crossing B6/SJL males harboring the transgene with
wild-type B6/SJL females. Housing of animals was performed
under a 12 h light/12 h dark cycle with free access to food and
water.
For genotyping, tail biopsies of 14-day-old pups were sub-
jected to a standardized PCR protocol (Jackson Labs). Probe
sequences were: hSOD1-forward, CATCAGCCCTAATCCAT
CTGA; hSOD1-reverse, CGCGACTAACAATCAAAGTGA;
Interleukin 2-forward, CTAGGCCACAGAATTGAAAGATCT,
Interleukin 2-reverse, GTAGGTGGAAATTCTAGCATCATCC).
Y-27632 was administered at a concentration of 2mg/kg body
weight per day (subsequently termed as Y2) or at a concentration
of 30mg/kg body weight per day (Y30) in drinking water accord-
ing to previous studies with Y-27632 in animal disease models
(Nagaoka et al., 2005). Control groups received drinking water
without supplementation (Veh).
CLINICAL AND BEHAVIORAL ANIMAL TESTING
Experimental groups
At day of life 50 (d50) mice were allocated to the different
treatment groups. In a first trial a Y-27632 dose of 2mg/kg
(Y2) was compared with vehicle (Veh). In a second trial a
Y-27632 dose of 30mg/kg (Y30) was compared with vehicle
(Veh). Both trials were performed in an observer-blinded fashion
and groups were constituted to minimize inter-group variabil-
ity by matching of animals with respect to body weight, age and
litter.
Assessment of neurological score, body weight and survival
Neurological scores and body weight were assessed every 3 days
for each mouse from 50 days of age. The neurological score
employed a scale of 0 (worst) to 4 (best) (Weydt et al., 2003).
Mice showing an inability to right themselves 30 s after being
placed on a side or having a 25% loss of their initial body
weight were scored as “dead,” and were euthanized using carbon
dioxide.
Rotarod test
After training for three consecutive times of at least 180 s at a con-
stant speed of 15 r.p.m. the time for which an animal could remain
on the rotating rod (Ugo-Basile, Comerio, Italy) was measured
(Gunther et al., 2012). The mean of three trials was recorded for
each animal.
Hanging wire test
Animals were placed on a custom-made wire lid (0.8 cm spacing)
and cautiously turned upside down, 60 cm above a straw-covered
bottom (Gunther et al., 2012). After training for three consecutive
times of at least 180 s the latency to fall was measured. The mean
of three trials was recorded.
STATISTICAL ANALYSIS
For in vitro experiments, the comparison between two groups
was carried out using an unpaired Student’s t-test. Behavioral
data were subjected to a multifactorial ANOVA analysis and post
hoc Fisher’s test. Survival data were analyzed using Kaplan-Meier
survival fit analysis with Log-Rank tests for statistical signif-
icance. Statistical analyses were performed using Statistica 10
(StatSoft, Hamburg, Germany) and Kyplot 2.0 (KyensLab Inc,
Tokyo, Japan). Data are represented as mean ± standard error of
the mean. Significances are ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
RESULTS
PHARMACOLOGICAL INHIBITION OF ROCK WITH Y-27632 INCREASES
SURVIVAL AND PROMOTES NEURITE OUTGROWTH OF
MOTONEURONS IN VITRO
Based on findings that ROCK inhibition is able to attenuate cell
death in CNS neurons we examined the neuroprotective potential
of Y-27632 in primary MN in dissociated cell culture. In compar-
ison to the number of surviving MN after 4 days in vitro in the
vehicle treated culture which was set to 100% (100.0 ± 5.3%), the
Y-27632 treated culture showed significantly higher numbers of
MN (123.7 ± 9.5%) (Figure 1A). This protective effect was also
observed in a cytotoxicity assay in which the release of adeny-
late kinase was reduced after Y-27632 treatment (Supplementary
Figure 1).
In the same cultures we measured the total neurite net and
calculated neurite length per MN in order to remain indepen-
dent from MN cell numbers. Compared to the vehicle control
treatment, which was set to 100% (100.0 ± 7.7%), application
of 10µM Y-27632 resulted in a significantly increased neurite
length of ChAT-immunopositive motoneurons (128.0 ± 11.8%)
(Figures 1B–D). In a dose-escalating experiment we observed
that a 10µM final dose of Y-27632 was superior to 5-fold lower
or higher doses, which were not significantly promoting neurite
outgrowth (Supplementary Figure 2).
The presence of ROCK2 in motoneurons was demon-
strated both immunocytochemically in ChAT immunopositive
cells and by immunoblot of cell culture lysates. Here, treat-
ment with Y-27632 was not found to influence the amount
of ROCK2 protein being expressed. However, the applica-
tion of Y-27632 resulted in altered growth cone morphology
with prolonged processes if compared to vehicle treated cells
(Figure 2).
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FIGURE 1 | Y-27632 increases survival of dissociated MN and promotes
neurite outgrowth. (A) Relative numbers of ChAT-immunopositive MN per
visual field on DIV4 in cultures treated with Veh or with Y-27632 (10µM)
(n = 3 MN cultures, bars represent means ± s.e.m.; ∗∗P < 0.005,
according to unpaired Student’s t-test). (B) Relative neurite length per
ChAT-immunopositive MN treated as in (A) (n = 2 MN cultures, bars
represent means ± s.e.m.; ∗∗∗P < 0.001, according to unpaired Student’s
t-test). (C,D) Representative photomicrographs of MN immunolabeled with
ChAT (Cy3, red) and treated with Veh (C) or Y-27632 (10µM) (D) (nuclear
counter-stain with DAPI, blue). Scale bar, 200µm.
WEIGHT DYNAMICS AND SURVIVAL OF Y-27632 TREATED MICE
In a proof-of-principle approach, we used the SOD1G93A mouse
model to assess the effects of oral Y-27632 treatment with 2mg/kg
body weight (Y2) and 30mg/kg body weight (Y30) compared
against vehicle (Veh) in a presymptomatic trial design starting at
day of life 50 (d50).
Female mice, which have been treated with Y30, had a slightly
higher weight in an advanced age, which was, however, not
reaching significance. The Y2 female treatment group was not dif-
ferent from vehicle control (Figures 3A–D). Male animals treated
with Y2 did not gain as much maximal weight as controls. The
Y30 male treatment group was not different from the control
(Figures 3E–H).
The analysis of mean survival times did not show a significant
improvement by Y-27632 treatment for any group (females: Veh
132,8 ± 1,9 days vs. Y2 130,8 ± 2,4 days; Veh 141,2 ± 2,5 days
vs. Y30 143,9 ± 3,4 days; males: Veh 125,9 ± 1,9 days vs. Y2
125,5 ± 2,2 days; Veh 132 ± 3,5 days vs. Y30 133,5 ± 2,6 days)
(Figure 4).
FIGURE 2 | Motoneurons express ROCK2 protein. Depicted are MN
treated with vehicle (A,E,G) or Y-27632 (10µM) (B,F,H). (A,B) ROCK2 is
localized primarily in the cytoplasm in both vehicle and Y-27632-treated MN.
(C) Quantification of perikaryal ROCK2 immunofluorescence (IF) in MN
(n = 6 cells, bars represent means ± s.e.m., according to unpaired
Student’s t-test). (D) Immunoblots of motoneuron cell cultures for ROCK2
and GAPDH. (E,F) MN harbor high amounts of f-actin (rhodamine-phalloidin,
red). (G,H) Magnifications of growth cone areas as depicted in (E,F). Scale
bar, 25µm.
NEUROLOGICAL SCORING AND MOTOR BEHAVIOR ARE IMPROVED IN
MALE MICE TREATED WITH HIGH DOSE OF Y-27632
In a detailed analysis of disease progression based on the
neurological score we found nearly no significant differences
between Y-27632 and Veh-treated groups. A significant effect
was, however, seen in Y30 treated male mice which showed
improved values for the neurological score from d107 until d122
(Figure 5).
In the analysis of motor coordination and muscle strength
as assessed by the ability to remain on a rotating rod, a sig-
nificant advantage was again detected for male mice treated
with Y30 in the time period from d80 until d113 (d104:
Veh 114,04 ± 30,24 s; Y30 168,17 ± 11,83 s; d107: Veh
117,13 ± 26,94 s; Y30 173,31 ± 6,69 s; d110: Veh 70,67 ±
22,90 s; Y30 145,79 ± 16,97 s; d113 Veh 50,29 ± 21,19 s;
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FIGURE 3 | Weight dynamics in relation to body weight at day 50 (start
of presymptomatic treatment) in SOD1G93A mice treated with 2 or
30mg/kg body weight Y-27632. (A–D) Weight dynamics in female mice
treated with Y-27632 from d50 in a dosage of 2mg/kg (A,B) (Y2 n = 13; Veh
n = 18) or 30mg/kg (C,D) (Y30 n = 13; Veh n = 12). (E–H) Weight dynamics
in male mice treated with Y-27632 from d50 in a dosage of 2mg/kg (E,F) (Y2
n = 10; Veh n = 14) or 30mg/kg (G,H) (Y30 n = 8; Veh n = 8). Statistics was
done applying multifactorial ANOVA and post-hoc Fisher’s test. ∗P < 0.05.
Y30 105,56 ± 20,31 s). Similarly, in the analysis of muscle
strength measured by hanging wire the vehicle group performed
worse in comparison to the Y30 male group, however, without
reaching significance. Animals treated with Y2 did not exhibit
improved motor behavior nor did any of the female cohorts
(Figure 6).
DISCUSSION
Motoneuron death and axonal degeneration are critical
pathogenic features in the development of human ALS (Fischer
et al., 2004). ROCK inhibition by fasudil was previously
shown to exert neuroprotective, but also pro-regenerative and
axon-stabilizing effects, but fasudil is a rather unspecific drug
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FIGURE 4 | Survival in SOD1G93A mice treated with 2 or 30mg/kg
body weight Y-27632. Depicted is a Kaplan-Meier curve for cumulative
probability of survival for female mice treated with 2mg/kg (A) (Y2 n = 13;
Veh n = 18) or 30mg/kg Y-27632 (B) (Y30 n = 13; Veh n = 12) and for male
mice treated with 2mg/kg (C) (Y2 n = 10; Veh n = 14) or 30mg/kg Y-27632
(D) (Y30 n = 8; Veh n = 8). Days ante mortem refers to the time point
before death of an individual animal measured in days. Statistics was done
applying Kaplan-Meier survival fit analysis with Log-Rank test.
in comparison to the more specific ROCK inhibitor Y-27632.
Therefore, we have now evaluated the therapeutic potential of
orally applied Y-27632 in the SOD1G93A mouse model of ALS.
PHARMACOLOGICAL INHIBITION OF ROCK PROTECTS MOTONEURONS
IN CULTURE
ROCK inhibitors have been applied successfully in a multitude
of cell death paradigms. They have shown to attenuate apoptotic
cell death of retinal ganglion cells (Lingor et al., 2008; Tura et al.,
2009) and prevent dopaminergic cell loss in toxin-based models
of Parkinson’s disease (Tonges et al., 2012). Recently, Y-27632 was
also shown to protect hippocampal neurons against neuronal cell
death induced by glutamate in vitro and by kainic acid in vivo
(Jeon et al., 2013).
In a model of kainate-induced glutamate excitotoxicity, our
group was able to demonstrate that the ROCK inhibitor fasudil
significantly increased the number of survivingMN (Tonges et al.,
2014). This neuroprotective effect was now also observed for
Y-27632, which reduced the loss of motoneurons in dissociated
cell culture. Furthermore, neurite outgrowth was promoted on a
permissive substrate—an effect, which is well known for ROCK
inhibitors if applied to neuronal cells (Lingor et al., 2008; Tonges
et al., 2012).
However, it has to be taken into account that there seems to be
an optimal dosage window for Y-27632 in vitro—as is known for
other ROCK inhibitors, too—because final concentrations of 2 or
50µM, being fivefold lower or higher than the optimal 10µM,
were not able to elicit a significant outgrowth promoting effect
of MN anymore. This could be due to the inhibition of protein
kinases other than ROCK which are known for both Y-27632 and
fasudil—however, to a much lower extent for Y-27632. In fact,
a concentration of 20µM fasudil is needed to reduce ROCK-II
activity in vitro to 7% of control and a concentration of 10µM
Y-27632 is needed to reduce ROCK-II activity in vitro to 13%.
The concentrations of both compounds required for 50% inhi-
bition (IC50) of ROCK2 are 1900 nM for fasudil and 800 nM for
Y-27632. Most importantly, the activities of several other kinases
are much stronger reduced with fasudil (20µM) (MAPKAP-K1b
37%, MSK1: 19%, PKA: 35%, S6K1 32%) than with Y-27632
(10µM) (MAPKAP-K1b: 72%, MSK1: 57%; PKA: 91%, S6K1
94%), which may elicit neurobiological side effects albeit being
difficult to predict.
THE DISEASE COURSE IN SOD1G93A MICE IS ONLY TRANSIENTLY
IMPROVED BY Y-27632 TREATMENT
In the evaluation of clinical symptoms of disease, we found only
a transient improvement for male mice with the high-dose Y30
treatment, which correlated with the transient improvement in
motor performance. In contrast, survival of SOD1G93A mice was
not significantly prolonged in this study in any group.
In a previous study of our group, we had orally applied the
more unspecific ROCK inhibitor fasudil to SOD1G93A mice start-
ing at postnatal day 50 (d50) (Tonges et al., 2014). Here, survival
was significantly prolonged with fasudil 30mg/kg and by trend
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FIGURE 5 | Neurological score in SOD1G93A mice treated with 2 or
30mg/kg body weight Y-27632. (A,B) Depicted are scores for female
mice treated with Y-27632 from d50 in a final dosage of 2mg/kg (A) (Y2
n = 13; Veh n = 18) or 30mg/kg (B) (Y30 n = 13; Veh n = 12). (C,D)
Scores for male mice treated with Y-27632 from d50 in a final dosage of
2mg/kg (C) (Y2 n = 10; Veh n = 14) or 30mg/kg (D) (Y30 n = 8; Veh
n = 8). Statistics was done applying multifactorial ANOVA and post-hoc
Fisher’s test. ∗P < 0.05.
with fasudil 100mg/kg. The smaller effect by fasudil 100mg/kg
could be due to a U-shaped dose-response relationship, which we
have observed before in vitro (Lingor et al., 2007; Tonges et al.,
2012). Similar effects of fasudil on survival in the SOD1G93A
model have been reported by another group who found a prosur-
vival response, which was attributed to an attenuation of ROCK
activity and an increased level of phospho-Akt (Takata et al.,
2013).
Other trials with Y-27632 in models of neurodegenera-
tive disease had shown more favorable results. In a model of
Huntington’s disease, the ROCK inhibitor Y-27632 improved
rotarod performance without influencing survival time at a
dosage of 100mg/kg (Li et al., 2009). The two ROCK inhibitors
Y-27632 (30mg/kg) and fasudil (30mg/kg) were also benefi-
cially applied in mouse models of SMA, in which they prolonged
survival and preserved the integrity of the neuromuscular junc-
tion (NMJ). Interestingly, the effect on survival was more pro-
nounced with fasudil than with Y-27632 (Bowerman et al., 2010,
2012).
Overall, the application of Y-27632 was less successful in the
SOD1G93A mousemodel than that of fasudil. Since 30mg/kg body
weight showed only significant effects onmotor function, we can-
not exclude that an even higher dosage would be more beneficial.
It could also be that the differential inhibitory profile toward other
kinases is responsible for the lack of efficacy (Davies et al., 2000).
Thus, some of these “off-target” effects on other kinases by fasudil
may have been even beneficial to a certain extent in this ALS
model.
GENDER-DIFFERENCES OF ROCK INHIBITION WITH Y-27632 IN THE
SOD1G93A MODEL
It is known that female mice have longer survival times in the
SOD1G93A mouse model than males. This fact has also been
observed in our study. However, a minor trend to improved
survival with Y-27632 is only seen in females treated with
30mg/kg Y-27632 but not in male mice. Interestingly, the tran-
sient improvement of motor function was detected only in male
mice on a significant level and was observed only by trend in
female mice. This could be due to a more aggressive disease
course associated with increased ROCK activity in intermediate
stages in male mice, which then benefit more from the Y-27632
application. Supportive of this hypothesis is a study that has
been performed in the MPTP model of Parkinson’s disease in
female mice. If these mice were ovariectomized, an increased
loss of dopaminergic neurons after MPTP toxicity was observed,
which was shown to be associated with an increase of ROCK
activity. Thus, higher ROCK activity correlated to increased vul-
nerability of dopaminergic neurons to MPTP. When Y-27632 was
applied in this model, the increased loss of dopaminergic cells
was reversed being as effective as an estrogen-replacement therapy
(Rodriguez-Perez et al., 2013).
CONCLUSION
The role of ROCK and the therapeutic potential of its inhibition
are increasingly studied in models of neurodegenerative disease.
However, findings obtained with one ROCK inhibitor may not be
generalized to the entire class of ROCK inhibitors, which show
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FIGURE 6 | Motor behavior in SOD1G93A mice treated with 2 or
30mg/kg body weight Y-27632. (A–D) Mean time of endurance on
the rotarod and in the hanging wire test for female mice treated with
Y-27632 from d50 in a dosage of 2mg/kg (A,B) (Y2 n = 13; Veh n = 18)
or 30mg/kg (C,D) (Y30 n = 13; Veh n = 12). (E–H) Scores for male
mice treated with Y-27632 from d50 in a dosage of 2mg/kg (E,F) (Y2
n = 10; Veh n = 14) or 30mg/kg (G,H) (Y30 n = 8; Veh n = 8). Statistics
was done applying multifactorial ANOVA and post-hoc Fisher’s test;
∗P < 0.05; ∗∗P < 0.01; in H: § d68 p = 0.12; § d101 p = 0.08; § d107
p = 0.12.
high chemical heterogeneity. Whereas the application of fasudil
was successfully promoting survival of SOD1G93A mice in two
independent studies, this was not found for Y-27632 in two dif-
ferent dosages in the present paradigm. Suboptimal targeting of
the therapeutic window as well as the differential inhibition of
other protein kinases may contribute to these differences. As most
studies have been performed in female mice, a gender-dependent
responsiveness to ROCK inhibition may play an additional role.
Our study thus supports the need for thorough evaluation of
ROCK inhibitors in models of neurodegenerative disease in order
to better characterize their effects and thereby optimally prepare
their translation into human clinical trials.
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